secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059527
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics Q1 net loss $16.6M; Phase 2 TR-MAC data expected August 2024
-----------------------------------------------------------------------------

- Net loss of $16.6M for Q1 2024 vs $15.3M in Q1 2023; cash $118.1M.
- R&D spend $14.7M, up from $12.0M YoY; G&A $3.6M, down from $4.1M.
- Phase 3 enrollment paused Feb 2024 due to blinded aggregate efficacy signal; no safety issues.
- 97 patients remain in Phase 3; topline Phase 2 data from EBO-301 due August 2024.
- Epetraborole targets treatment-refractory MAC lung disease with high unmet need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000095017024059527/0000950170-24-059527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000095017024059527/antx-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer